Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.39 |
| ▸ | HTR1D | P28221 | 4/20 | 0.39 |
| ▸ | HTR1B | P28222 | 4/20 | 0.39 |
| ▸ | CDK9 | P50750 | 6/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6179721 | 0.89 | HTR6 (0.39) | CDK9CCNT1ACHEDRD3HTR6 | |
| SCHEMBL6179195 | 0.84 | TP53 (0.44) | ACHEHTR6 | |
| SCHEMBL6180465 | 0.81 | HTR1A (0.59) | HTR1AHTR1DHTR1B | |
| SCHEMBL6180139 | 0.79 | HTR1A (0.39) | HTR1AHTR1DHTR1BACHEROCK1 | |
| SCHEMBL6178501 | 0.76 | HTR1A (0.38) | HTR1AHTR1DHTR1BCDK9CCNT1 | |
| SCHEMBL6370415 | 0.75 | BCHE (0.40) | ACHEHTR6 | |
| SCHEMBL6179764 | 0.74 | HTR2C (0.51) | HTR1AHTR1DHTR1BHTR6 | |
| SCHEMBL8117765 | 0.73 | ALK (0.43) | HTR1AHTR1DHTR1BDRD3HRH3 | |
| SCHEMBL6177192 | 0.71 | CDC7 (0.35) | CDK9CCNT1 | |
| SCHEMBL6179444 | 0.71 | PTGDR2 (0.37) | HTR1AHTR1DHTR1BACHEROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239797-A1 | Isoquinoline and quinazoline derivatives having a combined 5HT1A, 5HT1B, and 5HT1D receptor activity | SMITHKLINE BEECHAM, PLC | 2005-10-27 | — | — | US | disclosed |
| EP-1228043-B1 | ISOQUINOLINE AND QUINAZOLINE DEIVATIVES HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2005-01-12 | — | — | EP | disclosed |
| EP-1228043-A1 | ISOQUINOLINE AND QUINAZOLINE DEIVATIVES HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001032626-A1 | ISOQUINOLINE AND QUINAZOLINE DERIVATIVES HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ACTIVITY | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239797-A1 | Isoquinoline and quinazoline derivatives having a combined 5HT1A, 5HT1B, and 5HT1D receptor activity | HTR1B, HTR1A, HTR1D | HTR1A 2/4885HTR1D 3/4885HTR1B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.